Bispecific Antibodies: US FDA May Require Comparison To Approved Monospecific Product

When approved therapies target the same antigens as the investigational bispecific antibody, FDA may request a comparative clinical trial, draft guidance notes.

antibodies, immunoglobulins, banner 3D rendering - Illustration

Sponsors developing a bispecific antibody may need to conduct a clinical study comparing the therapy to an approved monospecific antibody that targets the same antigens, FDA notes in draft guidance.

"In many situations, the clinical studies for bispecific antibodies will compare the bispecific antibody to standard of care or placebo,"...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership